Communiqués Nexentis Technologies Inc.

Actions

NXTS

US80512Q6008

Produits chimiques destinée à l'agriculture

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 07/08/2026			Varia. 5j.	Varia. 1 janv.
1,890 ^USD	-1,82%		+10,53%	-83,93%

23/06	Les plus fortes baisses de la mi-séance	MT
23/06	Les plus fortes baisses de l'avant-bourse	MT

Communiqués

28/07	Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate for Drug Discovery Campaign	AQ
07/07	Nexentis Subsidiary MitoCareX Bio Advances SLC Transporter Drug Discovery with Broad Analysis and International AI Initiative	AQ
29/06	Nexentis Announces Monetization of Part of its Melz Solar Investment at $14.5 Million Project Valuation – Significant Premium to Initial Investment	AQ
22/06	Nexentis Technologies Announces International AI Drug Discovery Initiative Between MitoCareX Bio and Boltz to Accelerate Novel SLC Small-Molecule Discovery	AQ
17/06	Nexentis: Subsidiary MitoCareX Bio Successfully Completed Broad Analysis of SLC Transport Proteins to Support Discovery of Hard-to-Treat Cancers and Metabolic Diseases	AQ
18/05	Nexentis Announces MitoCareX Bio Achieves Key R&D Milestone, Generating a Substantially Improved Hit Molecule on the Path to Pre-Clinical Development	AQ
13/05	Nexentis Technologies Announces Optimization of Hit Molecule at MitoCareX Bio Representing Key Drug Discovery Milestone	AQ
05/05	Nexentis Technologies Announces U.S. Trademark Registration Approval for MitoCareX’s Algorithm Platform MITOLINE™	AQ
13/03	Nexentis Technologies Inc. Launches New Corporate Website, Showcasing Innovative AI-Driven Biotech Platform	AQ
25/02	N2OFF Announcing Corporate Rebranding as Nexentis Technologies - Innovative AI and Data Driven Computational Biotech Company	AQ
12/02	MitoCareX Bio Reports Successful Results in Vitro: MITOLINE™-Powered Small Molecules Show Anti-Inflammatory Potential for Metabolic Syndrome-Related Diseases	AQ
02/02	In Spaceflight Conditions: N2OFF‘s MitoCareX Bio Highlights Co-Founder's Innovative Research on Mitochondrial Carriers in Microgravity and Cosmic radiation Conditions	AQ
22/01	N2OFF: MitoCareX Bio Announces Positive In Vitro Results from Its Mitochondrial Carrier Small Molecule Platform	AQ
15/01	N2OFF: MitoCareX Bio Spotlights Co-Founder's Pioneering Research on Mitochondrial Carriers in Spaceflight Stress Conditions	AQ
05/01	N2OFF Advances $340,000 Payment to Gain Better Terms in Flag Solar Energy Initiative, Reflecting Approximately an Additional $1.7 Million in Project Profit Stake	AQ
29/12	N2OFF Accelerates European Renewable Energy Momentum with Major De-Risking Milestones and Approximately $1.69 Million Value Unlock in Germany and Italy	AQ
18/11	N2OFF: MitoCareX Identifies Hit Compounds and Targets Preclinical Candidate Nomination	AQ
23/10/25	N2OFF Announces Closing of Merger with Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer	AQ
08/10/25	N2OFF Regains Compliance with Nasdaq Minimum Bid Price Requirement	AQ
18/09/25	N2OFF Announces Reverse Stock Split	AQ
18/09/25	N2OFF Provides Business Update on Successful Execution of Solar and Energy Storage Initiatives Across Europe	AQ
11/09/25	N2OFF to Expand its Melz Solar Project with Battery Storage	AQ
11/07/25	N2OFF Completes $1.2 million of its $2.7 million Total Commitment to Finance 196MWp Battery Energy Storage Assets in Italy	AQ
16/06/25	N2OFF is Increasing its Investment in Melz Project to Explore Additional 40-60 MW Battery Storage	AQ
15/05/25	N2OFF Energy Targets European’s Energy Crises with Fourth Regional Battery Project	AQ